Contact Us

MED-C Secures Cornerstone Funding

MED-C has acquired the majority of operating funds needed to launch its first project, a registry based on next generation sequencing (NGS) in lung cancer.
    OWASSO, OK, October 23, 2015 /24-7PressRelease/ -- The Molecular Evidence Development Consortium (MED-C), a non-profit 501(c)(3) organization, is pleased to announce it has signed (or will shortly sign) funding agreements with the following companies:

Eli Lilly and Company
Illumina Inc.
Thermo Fisher Scientific

With the support of these industry-leading companies, MED-C has acquired the majority of operating funds needed to launch its first project, a registry based on next generation sequencing (NGS) in lung cancer.

"Although the complete MED-C NGS registry will encompass many different disease states, the starting point is the 'N1N Registry' where patients with newly diagnosed advanced non-small cell lung cancer will have the opportunity to have their tumor tested by high-quality, standardized NGS, be treated by the latest standard of care and have de-identified clinical outcomes collected in a centralized, open-access, database," said Dane J. Dickson M.D. the Chief Operating Officer of MED-C. "This project focuses the efforts and strengths of all major stakeholders (patients, providers, payors, regulators, pharma, and industry/laboratories) into building one of the greatest advances in personalized medicine ever undertaken. The generous support of these companies in both donations and expertise has allowed us to get this started. We hope that many others will join with them in helping us rapidly advance medicine in a way that we can only accomplish by working together."

After this pilot project gets off the ground, and as further support is obtained, MED-C plans to open up the NGS registry to other disease states and then through affiliated projects explore testing in areas such as proteomics, immunology, metabolomics, etc. Also, MED-C hopes that the registry will develop a strong future affiliation with clinical trials, thereby dramatically improving accrual in those already open (like the NCI-MATCH, Lung-MAP, ASCO TAPUR, etc.) and future trials that will be crucial to unlocking personalized medicine.

For further information, please contact MED-C at (208) 970-0244.

# # #

Read more Press Releases from Mary Jo Richards:

Comment on this story...

Share This Story

Email this Story

Contact Information

Mary Jo Richards
The Molecular Evidence Development Consortium

Owasso, Oklahoma
United States
Voice: 280-970-0244
E-Mail: Email Us Here
Website: Visit Our Website

Like This Story?

I like it! 0


If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release Newswire. We are unable to assist you with any information regarding this release. 24-7 Press Release Newswire disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.